Effects of adjunctive light-activated disinfection and probiotics on clinical and microbiological parameters in periodontal treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00023158

Enrollment

Registered

2020-09-30

Start date

2016-01-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K05.3

Interventions

Group 1: Periodontitis therapy using an ultrasonic device (EMS, Electro Medical Systems S.A., Nyon, Switzerland) and hand instruments (Hu-Friedy, Chicago, IL, USA) under local anesthesia (Ultracain® D

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: - diagnosis of periodontitis stage II or III and grade B - presence of at least six sites with PPD = 5mm - bleeding on probing - at least 20 remaining teeth

Exclusion criteria

Exclusion criteria: - diabetes mellitus - HIV - heart disease - osteoporosis - lactose intolerance - a positive history of periodontal or antibiotic treatment in the previous six months - smoking - pregnancy

Design outcomes

Primary

Measure	Time frame
The primary outcome measures were differences (in mm) between the groups for changes in pocket depth after 3 and 6 months compared to baseline. Probing pocket depth was measured from the free gingival margin to the bottom of the periodontal pocket with a conventional periodontal probe (PCP-UNC 15, Hu-Friedy®, Chicago, IL, USA).	—

Secondary

Measure	Time frame
Secondary outcome measures included clinical attachment level (mm), bleeding on probing, Gingiva-Index simplified, Plaque-Control-Record, and counts of the bacterial species. Clinical attachment level and bleeding on probing were measured at six sites per tooth (mesio-buccal, buccal, disto-buccal, disto-lingual, lingual and mesio-lingual) using a conventional periodontal probe (PCP-UNC 15, Hu-Friedy®, Chicago, IL, USA). Subgingival plaque samples were collected at baseline, 3 and 6 months following treatment from the deepest pocket of each quadrant. The samples were transferred to a sterile vial (pooled sample) and sent to a commercial laboratory for analysis. The analysis was performed with a commercially available DNA probe kit (IAI Pado Test, Institute of Applied Immunology, IAI, Zuchwil, Switzerland) to identify the following periopathogenic microorganisms: A. actinomycetemcomitans (Aa), T. forsythia (Tf), P. gingivalis (Pg), and T. denticola (Td).	—

Measure

Time frame

Secondary outcome measures included clinical attachment level (mm), bleeding on probing, Gingiva-Index simplified, Plaque-Control-Record, and counts of the bacterial species. Clinical attachment level and bleeding on probing were measured at six sites per tooth (mesio-buccal, buccal, disto-buccal, disto-lingual, lingual and mesio-lingual) using a conventional periodontal probe (PCP-UNC 15, Hu-Friedy®, Chicago, IL, USA). Subgingival plaque samples were collected at baseline, 3 and 6 months following treatment from the deepest pocket of each quadrant. The samples were transferred to a sterile vial (pooled sample) and sent to a commercial laboratory for analysis. The analysis was performed with a commercially available DNA probe kit (IAI Pado Test, Institute of Applied Immunology, IAI, Zuchwil, Switzerland) to identify the following periopathogenic microorganisms: A. actinomycetemcomitans (Aa), T. forsythia (Tf), P. gingivalis (Pg), and T. denticola (Td).

—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026